The anticoagulant drug Pradaxa received approval from the U.S. Food and Drug Administration (FDA) in late 2010. The intended function of Pradaxa is to prevent the development of blood clots and the occurrence of strokes in patients with atrial fibrilation, which causes irregular heartbeats. Since that time, a significant volume of litigation has been initiated by patients who have taken Pradaxa and subsequently suffered dangerous internal bleeding and severe abdominal complaints. Plaintiffs in these Pradaxa lawsuits have brought Pradaxa’s safety into serious question.
Pradaxa, also known as dabigatran etexilate, is an anticoagulant drug meant to inhibit the enzyme thrombin, which is responsible for clotting of the blood.
More than 2 million individuals in this country have been diagnosed with atrial fibrilation. One of the most commonly occurring heart rhythm concerns, this condition is characterized by a failure of the two top heart chambers to contract in a synchronized manner.
One of the primary risks associated with atrial fibrilation is the formation of blood clots. An individual clot has the potential to cause a debilitating stroke if it travels to the brain. The consequences of a stroke can include paralysis, serious cognitive damage as well as death.
Clinical studies indicated that patients taking Pradaxa suffered lower incidence of stroke than those taking warfarin, another anticoagulant often prescribed to patients under the trade name Coumadin. Such studies were intended to determine whether Pradaxa, produced by Boehringer Ingelheim Pharmaceuticals, offered a safe and effective treatment, and they yielded very encouraging results.
Following approval by the FDA, Boehringer Ingelheim made public its intention to produce Pradaxa in 75 and 150 milligram capsules. The firm also touted the fact that patients treated with Pradaxa would not need to undergo the type of routine blood monitoring necessary for those taking warfarin.
Side effects frequently reported by takers of Pradaxa have included serious or even deadly internal bleeding, though other anticoagulant drugs have also been known to produce similar problems. Because it has been known to cause such severe side effects, pharmacists are required by the FDA to dispense informational materials about the Pradaxa’s dangers every time a prescription for the drug is filled. Patients taking Pradaxa have also reported experiencing side effects such as bloating, stomach pain, heartburn and nausea.
Litigation Options for Those Adversely Affected by Pradaxa
If your experience with Pradaxa includes injuries such as internal bleeding or serious abdominal complications, you may be able to obtain substantial monetary compensation by taking part in Pradaxa litigation. In order to receive a thorough analysis of your claim, contact one of our skilled Pradaxa attorneys for a no-charge initial consultation. Another drug that has recently been in the news regarding lawsuits stemming from its side effects is Yaz, with serious side effects such as DEEP VEIN THROMBOSIS (DVT) reported.